<DOC>
	<DOC>NCT00800683</DOC>
	<brief_summary>to determine safety, efficacy and tolerability of BI 1356 versus placebo</brief_summary>
	<brief_title>Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) &lt;30 ml/min, who are not on chronic dialysis. Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%) Age 18 or over and not older than 80 years Exclusion criteria: Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent Unstable or acute congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>